S7201
SR-46349 hemifumarate salt
≥98% (HPLC)
别名:
4-((3Z)-3-(2-Dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate salt, Eplivanserin hemifumarate salt, SR-46349B
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C19H21FN2O2 · 0.5 C4H4O4
CAS号:
分子量:
386.42
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
powder
儲存條件
protect from light
顏色
white to off-white
溶解度
DMSO: ≥10 mg/mL
起源
Sanofi Aventis
儲存溫度
2-8°C
SMILES 字串
OC(=O)\C=C\C(O)=O.CN(C)CCO\N=C(\C=C\c1ccc(O)cc1)c2ccccc2F.CN(C)CCO\N=C(\C=C\c3ccc(O)cc3)c4ccccc4F
InChI
1S/2C19H21FN2O2.C4H4O4/c2*1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15;5-3(6)1-2-4(7)8/h2*3-12,23H,13-14H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b2*12-9+,21-19-;2-1+
InChI 密鑰
RNLKLYQQDLHHBH-ABDBJYMXSA-N
基因資訊
human ... HTR2A(3356)
應用
SR-46349 hemifumarate salt may be used in cell signaling studies.
生化／生理作用
SR-46349 is an antagonist of 5-HT (2A/2C) receptor and increases the release of dopamine by medial prefrontal cortex in rats.1 It increases the signal transduction induced by 5-HT2 receptor by binding with high affinity.2 SR-46349 inhibits the aggregation of rabbit and human platelets in response to serotonin.3
ASTAR (Antagonist of Serotonin 5HT2A Receptors).
特點和優勢
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Kevin T Ball et al.
Psychopharmacology, 181(4), 676-687 (2005-07-08)
Like amphetamine, a locomotor-activating dose of 3,4-methylenedioxymethamphetamine (MDMA) predominantly excites striatal single-unit activity in freely moving rats. Although both D1- and D2-like dopamine (DA) receptors play important roles in this effect, MDMA, unlike amphetamine, strongly increases both DA and serotonin
Stefania Bonaccorso et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 27(3), 430-441 (2002-09-13)
The combination of M100907, a putative antipsychotic drug (APD) and serotonin (5-HT)(2A) antagonist, and the typical APD haloperidol, can enhance dopamine (DA) release in rat medial prefrontal cortex (mPFC), an effect which has been postulated to be of value to
Christophe Lanteri et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 29(4), 987-997 (2009-01-30)
Although nicotine is generally considered to be the main compound responsible for addictive properties of tobacco, experimental data indicate that nicotine does not exhibit all the characteristics of other substances of abuse. We recently showed that a pretreatment with mixed
J M Herbert et al.
Thrombosis and haemostasis, 69(3), 262-267 (1993-03-01)
SR 46349 (trans-4-[(3Z)3-(2-dimethylaminoethyl)oxyimino-3(2-fluorophe nyl) propen-1-yl] phenol, hemifumarate) is the first member of a newly-developed 5-HT2 antagonist series. SR 46349 potently inhibited serotonin-induced aggregation of rabbit and human platelets (IC50 = 1 and 3.9 nM respectively) but had no effect on
Agnès Auclair et al.
The European journal of neuroscience, 20(11), 3073-3084 (2004-12-08)
Addictive properties of drugs of misuse are generally considered to be mediated by an increased release of dopamine (DA) in the ventral striatum. However, recent experiments indicated an implication of alpha1b-adrenergic receptors in behavioural responses to psychostimulants and opiates. We
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门